OmarEtonMDFACP

PubMed

• 205 citations
  Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
  Ken Wyman, Michael B. Atkins, Victor G. Prieto, Omar Eton, David F. McDermott
  Cancer. 2006-05-01
• 138 citations
  Phase II trial of imatinib mesylate in patients with metastatic melanoma
  K. B. Kim, Omar Eton, Darren W. Davis, Marsha L. Frazier, David J. McConkey
  British Journal of Cancer. 2008-08-26
• 59 citations
  Phase II evaluation of temozolomide in metastatic choroidal melanoma
  Agop Y. Bedikian, Nicholas Papadopoulos, Carl Plager, Omar Eton, Sigrid Ring
  Melanoma Research. 2003-06-01

Journal Articles

• Melanoma brain metastasis: overview of current management and emerging targeted therapies  
  Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper E, Eton O, Wong ET, Expert Rev Neurother, 1/1/2012
• Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors  
  Dees EC, Infante JR,Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H,4 Yih Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H, Cancer Chemotherapy & Pharmacology Cancer Chemother Pharmacol, 1/1/2010
• Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics  
  Macarulla T, Cervantes A, Elez E, Rodriguez-Braun E, Baselga J, Roselló S, Sala G, Blasco I, Danaee H, Lee Y, Ecsedy J, Shinde V, Chakravarty A, Bowman D, Liu H, Eton ..., Molecular Cancer Therapeutics, 1/1/2010
• Autologous tumor-derived heat-shock protein peptide complex-96 in patients with metastatic melanoma  
  Eton O, Savary CA, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Plager C, Bedikian AY, Reitsma D, Lee JE, J Transl Med, 1/1/2010
•  
  Kim, KB, Legha, SS, Gonzalez R, Anderson C, Papadopoulos NE, Eton O, Plager C, Roe A, Liu P, Bedikian AY, Melanoma Res, 1/1/2009
• Phase II Trial of Imatinib Mesylate in Patients with Metastatic Melanoma  
  Kim KB, Eton O, Davis D, McConkey D, Frazier M, Diwan AH, McGary E, Bar-Eli M, Ng C, Papadopoulos NE, Bedikian AY, Camacho LH, Billings L, Ross MI, Mansfield PF, Gersh..., British J Cancer, 1/1/2008
• Pilot Study of High-Dose Concurrent Biochemotherapy for Advanced Melanoma  
  Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm E, Bedikian AY, Cancer, 1/1/2004
• Analysis Of Protein Tyrosine-Kinase Expression In Melanocytic Lesions By Tissue Array  
  Shen SS, Zhang PS, Eton O, Prieto VG, J Cutan Pathol, 10/1/2003
• Low-dose immunotherapy does not increase survival when added to chemotherapy for advanced melanoma  
  Eton O, Journal of Evidence-Based Oncology, 1/1/2002
• Phase I trial of out-patient high dose subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma  
  Eton O, East M, Legha S, et al, Cancer, 1/1/2002
• Melanoma-Associated Retinopathy: A Harbinger of Recurrence for Cutaneous Melanoma  
  Esmaeli B, Naderi A, Ahmadi A, Wolin M, Eftekhari F, Safar S, Eton O, Int J Ophth and Visual Science, 1/1/2002
• Phase II evaluation of bryostatin-1 in metastatic melanoma  
  Bedikian AY, Plager C, Stewart JR, O'Brian CA, Herdman SK, Ross M, Papadopoulos N, Eton O, Ellerhorst J, Smith T, Melanoma Res, 1/1/2001
• A phase II study of "decrescendo" interleukin 2 plus interferon alpha 2a in metastatic melanoma progressing after chemotherapy  
  Eton O, Buzaid A, Bedikian A, et al, Cancer, 1/1/2000
• Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma  
  Bedikian A, Legha S, Eton O, et al, Anti-Cancer Drugs, 1/1/1999
• Pilot study of intra-arterial cisplatin and intravenous vinblastine and DTIC in patients with in-transit melanoma metastases  
  Eton O, East M, Legha S, et al, Mel Res, 1/1/1999
• Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases  
  Buzaid AC, Colome M, Bedikian A, Eton O, et al, Mel Res, 1/1/1998
• Hypercalcemia due to parathyroid hormone-related protein secretion by melanoma  
  Yeung SJ, Eton O, Burton DW, et al, Horm Res, 1/1/1998
• DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma  
  Buzaid AC, Ali-Osman F, Akande N, Grimm EA, Lee JJ, Bedikian A, Eton O, et al, Melanoma Res, 1/1/1998
• Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and Interleukin 2 for patients with me...  
  Legha SS, Ring S, Eton O, et al, J Clin Oncol, 1/1/1998
• Prognostic factors for survival of patients treated systemically for disseminated melanoma  
  Eton O, Legha SS, Moon TE, et al, J Clin Oncol, 1/1/1998
• Phase II trial of Tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma  
  Bedikian A, Legha S, Eton O, et al, Ann Oncol, 1/1/1997
• Critical Analysis of the Current AJCC Staging System for Cutaneous Melanoma and Proposal of a New Staging System  
  Buzaid AC, Ross MI, Balch CM, Soong SJ, McCarthy WH, Tinoco L, Mansfield P, Lee JE, Bedikian A, Eton O, et al, J Clin Oncol, 1/1/1997
• Development and results of biochemotherapy in metastatic melanoma: The University of Texas MD Anderson Cancer Center Experience  
  Legha SS, Ring S, Eton O, et al, Cancer J Sci Am, 1/1/1997
• Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon  
  Legha SS, Ring S, Bedikian A, Plager C, Eton O, , et al, Ann Oncol, 1/1/1996
• Phase II trial of recombinant human Interleukin-2 and Interferon alpha-2a; implications for the treatment of patients with metastatic melanoma  
  Eton O, Talpaz M, Lee KH, , et al, Cancer, 1/1/1996
• Join now to see all

Abstracts/Posters

• Phase I Evaluation of MLN8237, a Novel Aurora A Kinase Inhibitor
  Dees EC, Infante J, Burris H, O’Neil B, Murphy P, Eton O, Lee Y, Pappas J, Ecsedy JA, Cohen RB, Chemotherapy Foundation Symposium XXVI, 11/4/2008
• Dosing Strategies for MLN8054, a Selective Aurora A Kinase Inhibitor, Based on Pharmacokinetic Modeling and Simulations
  Lee Y, Eton O, Pappas J, Chen S, Paton M, EORTC-NCI-AACR 2008 Conference, 10/21/2008
• Phase I assessment of mechanistic pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase
  Chakravarty A, Shinde V, Bowman D, Galvin K, Silverman L, Stringer B, Danaee H, Eton O, Manfredi M, Ecsedy J, EORTC-NCI-AACR 2008 Conference, 10/21/2008
• MLN8237, an Oral Selective Aurora A Kinase Inhibitor: Initial Results of Dose-Finding Pharmacokinetic-Pharmacodynamic Phase I Study
  Tabernero Caturla J, Cervantes A, Elez E, Macarulla T, Rosello S, Rodríguez-Braun E, Stringer B, Shinde V, Danaee H, Eton O, EORTC-NCI-AACR 2008 Conference, 10/21/2008
• Phase I Study of the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of MLN8237, a Selective Aurora A Kinase Inhibitor, in the United States
  Infante J, Dees EC, Cohen RB, Burris H, O’Neil B, Murphy P, Lee Y, Pappas J, Ecsedy JA, Eton O, EORTC-NCI-AACR 2008 Conference, 10/21/2008
• Phase I and Pharmacokinetic Study of MLN8054, a Selective Inhibitor of Aurora A Kinase
  Dees EC, Infante JR, Cohen RB, O’Neil BH, Burris H, von Mehren M, Gray G, Galvin K, Manfredi M, Eton O, EORTC-NCI-AACR 2008 Conference, 10/21/2008
• Phase I clinical trial of MLN8054, a selective inhibitor of Aurora A kinase
  S. F. Jones, R. B. Cohen, E. C. Dees, Y. Lee, Eton O, J. A. Papas, M. R. Cooper, K. M. Galvin, H. A. Burris, Proc Am Soc Clin Oncol, 1/1/2007
• Phase II study of "hybrid" biochemotherapy for advanced melanoma
  Papadopoulos NE, Eton O, Kim KB, Camacho LH, Hwu P, Bedikian AY, Proc Am Soc Clin Oncol, 1/1/2006
• Phase II Trial of Imatinib Mesylate (STI-571) in Metastatic Melanoma (MM)
  Eton O, Billings L, Kim K, Prieto V, Davis D, Frazier ML, Diwan AH, McGary E, Papadopoulos N, Bedikian AY, Proc Am Soc Clin Oncol, 1/1/2004
• Pilot study of high dose concurrent biochemotherapy for advanced melanoma
  Kim KB, Eton O, East MJ, Plager C, Papadopoulos NE, Hodges C, Rohl C, Grimm EA, Bedikian AY, Proc Am Soc Clin Oncol, 1/1/2002
• Phase II evaluation of short IV infusion of paclitaxel in metastatic melanomBedikian AY, Papadopoulos N, Plager C, Eton O, Ellerhorst J, Smith T
  Bedikian AY, Papadopoulos N, Plager C, Eton O, Ellerhorst J, Smith T, Proc Am Soc Clin Oncol, 1/1/2002
• Clinical pharmacology studies of rhIL-2: Comparison of intravenous (IV) and subcutaneous (SC) routes
  Rosenblum MG, Zhang W, Eton O, Proc Am Assoc Cancer Res, 1/1/2000
• Psychosocial factors predict adjustment in cancer patients
  Cohen L, Eton O, Moor C, Amato R, East M, Proc SBM, 1/1/1999
• Phase I trial of out-patient high dose subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma
  Eton O, East M, Legha S, Bedikian A, Papadopoulos N, Buzaid A, Rosenblum MG, Benjamin RS, Proc Am Soc Clin Oncol, 1/1/1999
• The nurse clinician’s role in management of patients receiving autologous UVB-irradiated (UVR) whole melanoma cell vaccine
  Gianan M, Eton O, Kharkhevitch D, Proc ONS, 1/1/1998
• Phase II trial of tirapazamine (escalated dose) plus cisplatin in patients with advanced melanoma
  Bedikian AY, Legha SS, Buzaid AC, Eton O, Papadopoulos N, McIntyre S, Montogomery D, von Roemelling R, Proc Am Soc Clin Oncol, 1/1/1997
• Biochemotherapy studies in the treatment of advanced melanoma
  Legha SS, Bedikian A, Plager C, Eton O, Buzaid A, Papadopoulos N, Ross M, Mel Res, 1/1/1997
• Results of biochemotherapy in the treatment of advanced melanoma, The M. D. Anderson Cancer Center Experience
  Bedikian AY, Legha SS, Buzaid AC, Eton O, Papadopoulos N, Plager C, Ross M, Lee J, Mansfield P, Benjamin R, Mel Res, 1/1/1997
• In vitro DNA damage as predictor of response to biochemotherapy
  Buzaid AC, Ali-Osman FA, Akande N, Grimm EA, Lee JJ, Bedikian A, Eton O, Papadopoulos N, Plager C, Legha S, Benjamin R, Proc Amer Assoc Cancer Res, 1/1/1997
• In vitro DNA damage as predictor of response to biochemotherapy in melanoma
  Buzaid AC, Ali-Osman F, Akande N, Grimm EA, Lee JJ, Bedikian A, Eton O, Papadopoulos N, Plager C, Legha S, Benjamin R, Proc Amer Assoc Cancer Res, 1/1/1997
• A pilot study of interferon alfa-2b and cis-platin, velban and DTIC (CVD) in metastatic melanoma
  Plager C, Papadopoulos NE, Gianan MA, Bedikian AY, Buzaid AC, Eton O, Legha SS, Benjamin RS, Proc Am Soc Clin Oncol, 1/1/1996
• Neoadjuvant biochemotherapy in melanoma patients (pts) with local regional metastases (LRM)
  Buzaid AC, Legha S, Bedikian A, Eton O, Papadopoulos N, Plager C, Ross M, Lee J, Mansfield P, Strom E, Ring S, Rice J, Colome M, Benjamin R, Proc Am Soc Clin Oncol, 1/1/1996
• Phase II trial of tirapazamine plus cisplatin in patients with advanced melanoma. Proc Am Soc Clin Oncol 15:434, 1996.
  Bedikian AY, Legha SS, Buzaid AC, Eton O, Papadopoulos N, Coates S, Simmons T, von Roemeling R, Proc Am Soc Clin Oncol, 1/1/1996
• Phase II trial of Tirapazamine (TIRA) plus Cisplatin in patients (pts) with advanced malignant melanoma
  Bedikian A, Legha S, Buzaid A, Eton O, Papadopoulos NE, von Roemeling R, Sixth World Congress on Cancers of the Skin, 9/16/1995
• Durable complete responses (CR’s) in metastatic melanoma treated with biochemotherapy using cisplatin + vinblastine + DTIC (CVD) and IL-2 + interferon-alpha (IFN-alpha)
  Legha S, Ring S, Eton O, Plager C, Buzaid A, Papadopoulos N, Proc Am Soc Clin Oncol, 1/1/1995
• Join now to see all

Lectures

• Payment Reform 
  Best of ASCO, Boston, MA - 8/8/2014
• Preparing for a career in clinical translational research 
  1/1/2013
• Grand Rounds, Board Reviews... 
  Various locations - 1/1/2000